Hims & Hers: Undervalued Telehealth Juggernaut with Multiple Catalysts

2 months ago

"Number two, Hims and Hers. Hims is a telehealth company that sells prescription and over-the-counter treatments online. We've been fans of this one since last fall when it was trading at lower prices, and now it's all the way back down, which I believe is a great deal. The company is massively growing its revenue and subscriber numbers, with upcoming catalysts like Canada and Europe launches, GLP1 expansion, and new partnerships in weight loss and hormone health. Holding key support at $40.50 and fighting off bears, Hims presents an asymmetric reward opportunity for long-term investors."

The speaker advocates for Hims based on its strong revenue and subscriber growth, clear strategic catalysts, and technical support levels. The stock's current discount compared to its potential in an expanding telehealth market makes it a compelling long-term buy.

Related Stocks